Clinical Trial Detail

NCT ID NCT01653470
Title Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

lung non-small cell carcinoma

triple-receptor negative breast cancer

Advanced Solid Tumor

Therapies

Carboplatin

Fluorouracil + Irinotecan + Leucovorin

BMS-906024

Paclitaxel

Age Groups: adult

No variant requirements are available.